好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Highly Frequent MAPT p.R406W Carriers with a Nonconforming FTD Phenotype in the Belgian Flemish Population
Aging, Dementia, and Behavioral Neurology
S33 - Aging and Dementia: Non-Alzheimer Dementia (4:30 PM-4:42 PM)
006

We aimed at analyzing the phenotypical and genetic characteristics of patients carrying the p.R406W in the tau gene MAPT. Carriers present clinically with a nonconforming phenotype, with an underlying frontotemporal lobe degeneration (FTLD) pathology.

The p.R406W mutation is known to segregate in an autosomal dominant manner. In several pedigrees patients were reported with an amnestic (AD)-like phenotype. In our Flemish-Belgian population we identified 10 index patients with the p.R406W mutation. Additional family members of 3 of them were included, resulting in a total cohort of 56 mutation carriers. Haplotype sharing analysis confirmed genetic kinship between patients and families suggesting the presence of a common ancestor. 

We gathered data with longitudinal follow-up over 19 years and assembled results of clinical diagnoses, neuropsychological testing, cerebral imaging and cerebrospinal fluid (CSF) biomarkers. We investigated the potential modifying effect of the MAPT H1/H2 haplotype and the APOE genotype on onset age, disease duration, age at death and diagnosis. We compared the results with carriers of other FTLD genes (C9orf72, GRN, TBK1).

We compiled the data of 56 mutation carriers (3 pedigrees and 7 unrelated patients). Mean onset age and disease duration were 59.5 and 13 years. The most frequent clinical diagnoses were dementia (unspecified) (45.9%), AD (27.0%) and behavioral variant frontotemporal dementia (bvFTD) (24.3%). Frontal disinhibition and pronounced behavioral changes occurred in 71.4% patients. No modifying effect was shown of the MAPT H1/H2 haplotype and the APOE genotype.

The observations of the MAPT p.R406W carriers in the Flemish-Belgian cohort and families differ from earlier reports which showed amnestic presentation closely resembling AD. We obtained a high ratio (24.3%) of bvFTD diagnoses. Moreover, in other patients, prominent behavioral symptoms were highly frequent (71.4%). The MAPT H1/H2 haplotype and the APOE genotype did not modify onset age, disease duration, age at death or diagnosis.

Authors/Disclosures
Helena Gossye (VIB CMN)
PRESENTER
Mrs. Gossye has nothing to disclose.
Sara Van Mossevelde (University of Antwerp - CDE) The institution of Ms. Van Mossevelde has received research support from King Baudouin Foundation - Fund Mr and Ms Deelen-Hollanders.
Julie Van Der Zee No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Patrick Cras, MD, PhD (University of Antwerp) The institution of Dr. Cras has received research support from Belgian Fund for Scientific Research. Dr. Cras has received personal compensation in the range of $0-$499 for serving as a member with National Bioethics Committee.
Sebastiaan Engelborghs, MD, PhD (University of Antwerp, Biomedical Sciences) No disclosure on file
Peter P. De Deyn, MD, PhD Dr. De Deyn has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for elsevier.
Christine Van Broeckhoven, PhD (University of Antwerp - CDE) Dr. Van Broeckhoven has nothing to disclose.